Results 11 to 20 of about 38,450 (306)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Pharmaceuticals, 2021
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit ...
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Giuseppe Curigliano   +5 more
doaj   +1 more source

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Frontiers in Oncology, 2023
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers suitable for targeting by immunotherapies. First, the addition of the anti-CD20 monoclonal antibody
David A. Russler-Germain, David A. Russler-Germain, Armin Ghobadi, Armin Ghobadi   +3 more
doaj   +1 more source

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

Modular chemical construction of IgG-like mono- and bispecific synthetic antibodies (SynAbs)

, 2022
In recent years there has been rising interest in the field of protein–protein conjugation, especially related to bispecific antibodies (bsAbs) and their therapeutic applications.
Jaine K., Blayney, James R., Baker, Ioanna A., Thanasi, Fabien, Thoreau, Peter A., Szijj, Léa N. C., Rochet, Vijay, Chudasama, Michelle K., Greene, Antoine, Maruani, Christopher J., Scott   +9 more
core   +1 more source

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Kettenberger, Hubert, Thomas, Markus, Imhof-Jung, Sabine, Fenn, Sebastian, Christian B Schiller, Harald Duerr, Julia J Griese, Griese, Julia J., Sebastian Fenn, Schiller, Christian B., Regula, Joerg Thomas, Sebastian Fenn, Schaefer, Wolfgang, Christian Klein, Klein, Christian, Christian Gassner, Hubert Kettenberger, Markus Thomas, Gassner, Christian, Julia J. Griese, Hopfner, Karl Peter, Wolfgang Schaefer, Christian B. Schiller, Karl-Peter Hopfner, Moelleken, Joerg, Hopfner, Karl-Peter, Joerg Moelleken, Joerg Thomas Regula, Sabine Imhof-Jung   +29 more
core   +1 more source

Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second Generation

, 2023
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering ...
Rika, Takasugi, Yutaka, Matsuda, Kenichiro, Ito, Tomohiro, Fujii, Tomohiro, Watanabe, Masahiro, Yasunaga, Tsubasa, Aoki, Takuya, Seki, Hirobumi, Fuchigami, Yusuke, Iwai, Ryusuke, Hirama, Ryo, Tsumura, Kazutoshi, Takahashi   +12 more
core   +1 more source

A bispecific aptamer sensor towards T-cell leukemia detection in the tumor microenvironment

, 2021
The current detection methods of malignant cells are mainly based on the high expression levels of certain surface proteins on these cells. However, many of the same surface marker proteins are also expressed in normal cells.
Lina, Freage, Prabodhika, Mallikaratchy, Jared, Lenn, Natalie, Boykoff   +3 more
core   +1 more source

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

OncoImmunology, 2018
We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM).
Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Annette Hasenburg, Ruth Seggewiss-Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B. Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler   +16 more
doaj   +1 more source

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Antibodies, 2019
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying   +10 more
doaj   +1 more source